News
Galectin Therapeutics to Present at 2nd Annual NASH Summit 2018
April 18, 2018 | Press ReleaseGalectin Therapeutics Late-Breaker Presentation at The International Liver Congress Reinforces and Extends the Positive Effects of GR-MD-02 in Patients With NASH Cirrhosis
April 16, 2018 | Presentation
View the latest Galectin Therapeutics Corporate Presentation
A general overview of the company's activities and Clinical Phase studies with the Galectin-3 inhibitor GR-MD-02.
Supplemental presentation on GR-MD-02 for indication of NASH Cirrhosis
A detailed review of the results of the NASH-CX Clinical Trial.
Supplemental presentation on GR-MD-02 for Combination Cancer Immunotherapy
A detailed review of the use of GR-MD-02 in combination therapy with KEYTRUDA in advanced melanoma.
Galectin Therapeutics, Inc.